Tyro Capital Management LLC Has $24.94 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Tyro Capital Management LLC lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 20.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,108,283 shares of the company’s stock after acquiring an additional 353,307 shares during the period. Roivant Sciences accounts for 8.2% of Tyro Capital Management LLC’s portfolio, making the stock its 6th largest position. Tyro Capital Management LLC owned 0.29% of Roivant Sciences worth $24,941,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Rafferty Asset Management LLC boosted its stake in Roivant Sciences by 8.4% in the 4th quarter. Rafferty Asset Management LLC now owns 722,429 shares of the company’s stock worth $8,546,000 after purchasing an additional 55,960 shares in the last quarter. Patient Square Capital LP boosted its stake in Roivant Sciences by 2.1% in the 4th quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock worth $147,638,000 after purchasing an additional 251,535 shares in the last quarter. Nomura Holdings Inc. boosted its stake in Roivant Sciences by 8.6% in the 4th quarter. Nomura Holdings Inc. now owns 56,989 shares of the company’s stock worth $674,000 after purchasing an additional 4,489 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Roivant Sciences by 22.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 179,266 shares of the company’s stock worth $2,121,000 after purchasing an additional 32,329 shares in the last quarter. Finally, Lionshead Wealth Management LLC acquired a new position in shares of Roivant Sciences in the fourth quarter valued at about $118,000. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th.

Roivant Sciences Trading Up 0.3%

Shares of ROIV stock opened at $10.79 on Friday. The company has a market capitalization of $7.70 billion, a P/E ratio of -71.93 and a beta of 1.23. The business’s 50 day moving average is $10.51 and its two-hundred day moving average is $11.08. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06.

Insiders Place Their Bets

In other news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $10.65, for a total value of $1,065,000.00. Following the completion of the sale, the chief operating officer now directly owns 896,869 shares of the company’s stock, valued at approximately $9,551,654.85. The trade was a 10.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the transaction, the insider now owns 39,799,611 shares of the company’s stock, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,223,959 shares of company stock valued at $13,420,035 over the last quarter. 7.90% of the stock is owned by insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.